LIR1 Antibody

What is LIR-1/LILRB1 and what is its immunological significance?

LIR-1 (also known as LILRB1 or CD305) is an immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing receptor widely expressed on human immune cells, including B cells, monocytes, macrophages, dendritic cells, and subsets of natural killer (NK) cells and T cells. It functions as an immune inhibitory receptor that, when activated by ligands such as major histocompatibility complex (MHC) class I molecules, transduces suppressive signals that inhibit immune responses . LILRB1 is classified as a specialized type I transmembrane glycoprotein that modulates interactions within the tumor microenvironment and across the immune system. Its importance has been increasingly recognized in anti-cancer immunotherapy and pathogen defense mechanisms .

What methodologies are most effective for measuring LILRB1 expression in patient samples?

Flow cytometry remains the gold standard for quantifying LILRB1 expression on immune cell populations from patient samples. Research has demonstrated that LILRB1 expression can be significantly higher in patients with persistent multiple myeloma after treatment compared to healthy donors. Similarly, the percentage of LILRB1+ NK cells has been shown to be significantly elevated in patients with late-stage prostate cancer compared to healthy controls . When designing such experiments, it is crucial to include appropriate isotype controls and to analyze multiple immune cell subsets simultaneously to understand the cell type-specific expression patterns. Additional techniques such as immunohistochemistry for tissue sections and qPCR for transcriptional analysis can provide complementary information about LILRB1 expression profiles in different contexts.

How do LILRB1-containing natural antibodies contribute to antibody diversity?

The discovery of public antibodies targeting Plasmodium falciparum-encoded repetitive interspersed families of polypeptides (RIFINs) that contain extracellular immunoglobulin-like domains from LILRB1 represents a significant advancement in understanding antibody diversity mechanisms. These antibodies arise from unique B cell clones and demonstrate extensive cross-reactivity through their interaction with P. falciparum RIFINs . This phenomenon involves an innovative method of integrating extra exons into the antibody switch region, enriching the strategies for generating varied arrays of bispecific and multispecific antibodies. This mechanism provides new insights into both malaria parasite evasion strategies and the immune system's response capabilities, potentially opening new avenues for therapeutic antibody design beyond traditional variable domain engineering approaches .

What molecular mechanisms underlie the immunosuppressive effects of LILRB1 signaling in the tumor microenvironment?

LILRB1 signaling exerts immunosuppressive effects through multiple molecular pathways. When engaged by its ligands, LILRB1's intracellular ITIMs become phosphorylated, recruiting phosphatases SHP-1 and SHP-2 . These phosphatases subsequently dephosphorylate key signaling molecules in immune activation pathways, effectively dampening immune cell functions. In NK cells, this inhibits cytotoxic activity against cancer cells by interfering with activating receptor signaling cascades . In T cells, LILRB1 signaling can suppress TCR-mediated activation, proliferation, and cytokine production. In myeloid cells, including dendritic cells and macrophages, LILRB1 activation can induce a tolerogenic phenotype that further contributes to immune suppression in the tumor microenvironment. Single-cell RNA sequencing analysis has revealed that LILRB1 blockade increases CD4 memory T cells and inflammatory macrophages while decreasing pro-tumor macrophages, regulatory T cells, and plasmacytoid dendritic cells, suggesting complex regulatory effects across multiple immune cell types .

What techniques are optimal for measuring anti-LILRB1 antibody affinity and specificity?

Several complementary techniques are essential for comprehensive characterization of anti-LILRB1 antibody affinity and specificity. For precise affinity measurements, the Octet RED96 binding assay system has proven effective. In this approach, antibodies (typically at 30 μg/mL) are loaded onto protein G biosensors followed by exposure to recombinant LILRB1 at various concentrations (0.1–133 nM). By fitting data to a 1:1 binding model, researchers can extract association (kon) and dissociation (koff) rates, with the KD calculated as koff/kon. High-quality antagonistic antibodies typically demonstrate KD values in the range of 0.44-1.31 nM .

For specificity testing, ELISA provides a foundation where LILRB1 recombinant proteins are coated on plates, and serial dilutions of antibodies are added to determine EC50 values, which should be in the low nanomolar range (0.05-0.3 nM) for effective candidates. Cross-reactivity must be assessed against related proteins, particularly GPVI (which shares collagen-binding properties with LILRB1) and other LILR family members. Flow cytometry with cells naturally expressing LILRB1 further validates binding specificity in a cellular context . All data should be processed using specialized software such as ForteBio Octet Data Analysis Software V.9.0 to ensure accuracy and reproducibility .

What functional assays best evaluate the efficacy of antagonistic anti-LILRB1 antibodies?

Functional evaluation of antagonistic anti-LILRB1 antibodies requires a multi-tiered approach to confirm both blocking capacity and downstream immunomodulatory effects. Initially, LILRB1 chimeric receptor reporter cells provide a controlled system to assess an antibody's ability to neutralize ligand-induced LILRB1 activation. Effective antibodies should block LILRB1 activation by multiple ligands, including collagens, C1q, MBL, Colec12, and RIFINs .

For immunological function assessment, NK cell cytotoxicity assays against cancer cell lines (including multiple myeloma, leukemia, lymphoma, and solid tumors) demonstrate the antibody's capacity to enhance immune-mediated tumor killing. These should be conducted both with purified NK cells and in mixed cultures that include FcR-expressing cells to simulate in vivo conditions. Additionally, assays measuring T cell activation (proliferation, cytokine production), macrophage polarization, and dendritic cell maturation provide comprehensive insights into the antibody's effects across multiple immune cell types .

Importantly, these assays should be performed with cells from both healthy donors and cancer patients to account for disease-specific alterations in LILRB1 expression and responsiveness. The combined results from these diverse functional assays provide robust evidence of an antibody's antagonistic efficacy and therapeutic potential .

How should researchers design in vivo experiments to evaluate anti-LILRB1 antibody efficacy in cancer models?

Designing robust in vivo experiments for anti-LILRB1 antibody evaluation requires careful consideration of several factors. First, appropriate model selection is crucial: both syngeneic models using human LILRB1 transgenic mice and humanized mouse models reconstituted with human cord blood CD34+ cells have proven effective for evaluating anti-tumor responses. For metastatic studies, researchers should employ models like the MDA-MB-231 xenograft, which allows assessment of both primary tumor control and metastatic spread .

Experimental design should include multiple treatment groups (isotype control, anti-LILRB1 antagonist, and potentially combination with established therapies) with sufficient sample size for statistical power (typically n≥9 per group). Dosing regimens should be carefully optimized, with pharmacokinetic studies to confirm adequate antibody exposure. Multiple readouts should be incorporated: survival analysis (Kaplan-Meier), tumor volume measurements, metastatic burden assessment (liver weight, surface nodule counts, H&E staining), and comprehensive immune profiling of both tumors and secondary lymphoid organs using flow cytometry and immunohistochemistry .

Single-cell RNA sequencing of tumor-infiltrating immune cells provides invaluable insights into treatment-induced changes in the immune landscape. Importantly, Fc modifications (such as LALA-PG mutations) that eliminate effector functions should be considered to focus specifically on LILRB1 signaling blockade rather than depletion of LILRB1-expressing cells . All animal studies must be conducted under approved protocols (e.g., IACUC) with appropriate ethical considerations .

What analytical approaches best characterize the impact of LILRB1 blockade on immune cell populations?

Comprehensive analysis of LILRB1 blockade effects on immune populations requires integrated multi-modal approaches. Flow cytometry provides quantitative assessment of changes in immune cell subsets following treatment. Key populations to monitor include NK cells (CD3-CD56+), T cell subsets (CD4+ memory, CD8+ effector, and regulatory T cells), and myeloid populations (inflammatory vs. pro-tumor macrophages, dendritic cell subsets, and myeloid-derived suppressor cells) .

Single-cell RNA sequencing offers unprecedented resolution of treatment-induced changes, revealing not only shifts in cellular abundance but also alterations in functional states and gene expression profiles. This technology has demonstrated that LILRB1 blockade increases CD4 memory T cells and inflammatory macrophages while decreasing pro-tumor macrophages, regulatory T cells, and plasmacytoid dendritic cells .

Spatial transcriptomics or multiplex immunohistochemistry provides critical information about the geographical distribution of immune cells within tumors, helping to distinguish between peripheral and central infiltration patterns. Functional assays measuring cytokine production, cytotoxicity, and proliferation complement these phenotypic analyses. Data integration using computational approaches such as trajectory analysis and gene regulatory network inference can reveal mechanistic insights into how LILRB1 blockade reshapes the tumor immune landscape. Comparative analysis between responders and non-responders may identify predictive biomarkers for patient stratification in future clinical applications .

What considerations are crucial when designing anti-LILRB1 antibodies for clinical translation?

Translating anti-LILRB1 antibodies from research to clinical applications requires addressing several critical design considerations. First, epitope selection is paramount - the antibody should target domains that effectively block interactions with physiologically relevant ligands (collagens, MHC class I, C1q, etc.) while minimizing potential cross-reactivity with related receptors. Since LILRB1 is expressed on numerous immune cell types, potential toxicity must be carefully evaluated. Engineering antibodies with Fc modifications (such as LALA-PG mutations) that eliminate effector functions while maintaining blocking capacity can mitigate the risk of depleting LILRB1-expressing immune cells indiscriminately .

Humanization or de novo human antibody development is essential to reduce immunogenicity. Comprehensive binding kinetics (kon, koff, KD) should be optimized, with successful candidates typically showing KD values in the sub-nanomolar range. Manufacturing considerations including stability, aggregation propensity, and developability assessments are crucial for clinical feasibility .

Preclinical safety studies must include dose-ranging experiments in non-human primates (as LILRB1 is primate-restricted) with extensive immunophenotyping to detect potential immune dysregulation. Target engagement biomarkers and pharmacodynamic readouts should be established to guide clinical dosing. Finally, rational combination strategies with existing immunotherapies (anti-PD-1, anti-CTLA-4) should be explored preclinically to inform clinical development, as LILRB1 represents a promising complementary pathway to current immune checkpoint targets .

How can researchers address potential cross-reactivity issues when using anti-LILRB1 antibodies?

Addressing cross-reactivity in anti-LILRB1 antibody development requires systematic validation across multiple platforms. Researchers should implement a hierarchical screening strategy beginning with ELISA-based binding against a comprehensive panel of related proteins, particularly GPVI (which shares collagen-binding properties), other LILR family members (LILRB1-5, LILRA1-6), and species homologs . This initial screen should be followed by surface plasmon resonance or bio-layer interferometry to quantify any low-affinity cross-reactivity that might be missed in ELISA.

For antibodies that pass initial screens, cell-based validation is essential using flow cytometry with cells expressing individual LILR family members or related receptors. Critically, functional specificity must be confirmed using receptor-specific reporter assays to ensure the antibody blocks LILRB1 signaling without affecting related pathways. For advanced candidates, tissue cross-reactivity studies across multiple human tissues can identify unexpected binding targets .

When cross-reactivity is detected, epitope engineering guided by structural studies can help refine specificity. In cases where perfect specificity cannot be achieved, comprehensive characterization of cross-reactive targets enables informed risk assessment. Importantly, all specificity data should be documented thoroughly to guide appropriate experimental controls and interpretation of results in complex biological systems where multiple related receptors may be present .

What methodological approaches can improve the interpretation of LILRB1 blockade effects in heterogeneous tumor microenvironments?

Dissecting LILRB1 blockade effects in heterogeneous tumor microenvironments requires integrated methodological approaches that account for cellular diversity and spatial organization. Single-cell RNA sequencing combined with TCR/BCR repertoire analysis provides high-resolution mapping of immune cell phenotypes, activation states, and clonal relationships. This approach has revealed that LILRB1 blockade increases CD4 memory T cells and inflammatory macrophages while decreasing immunosuppressive populations .

Spatial transcriptomics or multiplex immunohistochemistry adds crucial information about cellular proximity and interaction networks. These techniques can identify whether LILRB1 blockade alters the spatial distribution of immune cells relative to tumor cells or affects the formation of tertiary lymphoid structures. Time-course experiments capturing dynamics of response are essential, as effects on different immune populations may follow distinct temporal patterns .

In vivo imaging using reporter systems can track immune cell trafficking and activation in real-time. When interpreting results, computational deconvolution approaches like CIBERSORTx can estimate cellular composition from bulk tissue transcriptomics, while trajectory inference algorithms can map cellular state transitions induced by treatment. Validation across multiple tumor models with varying baseline immune infiltration patterns is crucial to distinguish model-specific from generalizable effects. Finally, correlation with parameters like tumor mutational burden, MHC expression levels, and collagen deposition can identify contextual factors that influence response magnitude to LILRB1 blockade .